A macroprolactinaemia és a hyperprolactinaemia differenciáldiagnosztikája.

Translated title of the contribution: Macroprolactinemia in the differential diagnosis of hyperprolactinemia

Erzsébet Toldy, Zoltán Löcsei, I. Szabolcs, Pál Kneffel, M. Góth, Dominika Szöke, G. Kovács

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

INTRODUCTION: Biologically active prolactin and the inactive fraction of macroprolactin can be present in hyperprolactinaemic sera. The reaction of routinely used prolactin assays with macroprolactin is variable. AIMS: The present study was undertaken to analyse the leading clinical signs of hyperprolactinemia in macroprolactinemia and true hyperprolactinemia and to assess the prevalence of macroprolactinemia in hyperprolactinemic females. METHODS: 1571 consecutive female patients were investigated for hyperprolactinemia. Prolactin was measured before and after precipitation of macroprolactin by polyethylene glycol in 285 hyperprolactinemic (> 520 mlU/l) patients. Since not a single case of macroprolactinemia (recovery <40%) was found in the range of 520-700 mlU/l, only in women with prolactin > 700 mlU/l (N = 254) entered the study. RESULTS: In 59 patients (23%) macroprolactinemia was found. In women, the occurrence of macroprolactinemia increased with advancing age (p <0.05). "A priori" clinical signs indicating hyperprolactinemia occurred less frequently in patients with macroprolactinemia than in those with true hyperprolactinemia. Pituitary microadenoma was found in 9.8% of macroprolactinemia vs. 31.6% in true hyperprolactinemia (p <0.01); galactorrhea: 4% in macroprolactinemia vs. 19% in true hyperprolactinemia, (p <0.05); infertility: 17% in macroprolactinemia vs. 44% in true hyperprolactinemia (p <0.05). In 8 out of 59 women with macroprolactinemia, true hyperprolactinemia appeared simultaneously (15.3%). Occurrence of polycystic ovaries syndrome was more frequent in the true hyperprolactinemia (12%) that in macroprolactinemia (4.5%). CONCLUSIONS: It has been shown that macroprolactin does not occur in mild hyperprolactinemia. In women, the occurrence of macroprolactinemia increases with age. "A priori" clinical signs indicating hyperprolactinemia and pituitary abnormality are less frequent in macroprolactinemia than in true hyperprolactinemia. The diagnosis of macroprolactinemia should be used only, when the PRL levels fall to the normal range after precipitation. To avoid diagnostic and therapeutic pitfalls the screening for macroprolactin of all patients with prolactin > 700 mlU/L is recommended.

Original languageHungarian
Pages (from-to)2121-2127
Number of pages7
JournalOrvosi Hetilap
Volume144
Issue number43
Publication statusPublished - Oct 26 2003

Fingerprint

Hyperprolactinemia
Prolactin
Differential Diagnosis
Serum
polymeric prolactin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A macroprolactinaemia és a hyperprolactinaemia differenciáldiagnosztikája. / Toldy, Erzsébet; Löcsei, Zoltán; Szabolcs, I.; Kneffel, Pál; Góth, M.; Szöke, Dominika; Kovács, G.

In: Orvosi Hetilap, Vol. 144, No. 43, 26.10.2003, p. 2121-2127.

Research output: Contribution to journalArticle

Toldy, E, Löcsei, Z, Szabolcs, I, Kneffel, P, Góth, M, Szöke, D & Kovács, G 2003, 'A macroprolactinaemia és a hyperprolactinaemia differenciáldiagnosztikája.', Orvosi Hetilap, vol. 144, no. 43, pp. 2121-2127.
Toldy E, Löcsei Z, Szabolcs I, Kneffel P, Góth M, Szöke D et al. A macroprolactinaemia és a hyperprolactinaemia differenciáldiagnosztikája. Orvosi Hetilap. 2003 Oct 26;144(43):2121-2127.
Toldy, Erzsébet ; Löcsei, Zoltán ; Szabolcs, I. ; Kneffel, Pál ; Góth, M. ; Szöke, Dominika ; Kovács, G. / A macroprolactinaemia és a hyperprolactinaemia differenciáldiagnosztikája. In: Orvosi Hetilap. 2003 ; Vol. 144, No. 43. pp. 2121-2127.
@article{993bd39007534b9b8e01445836bfb26f,
title = "A macroprolactinaemia {\'e}s a hyperprolactinaemia differenci{\'a}ldiagnosztik{\'a}ja.",
abstract = "INTRODUCTION: Biologically active prolactin and the inactive fraction of macroprolactin can be present in hyperprolactinaemic sera. The reaction of routinely used prolactin assays with macroprolactin is variable. AIMS: The present study was undertaken to analyse the leading clinical signs of hyperprolactinemia in macroprolactinemia and true hyperprolactinemia and to assess the prevalence of macroprolactinemia in hyperprolactinemic females. METHODS: 1571 consecutive female patients were investigated for hyperprolactinemia. Prolactin was measured before and after precipitation of macroprolactin by polyethylene glycol in 285 hyperprolactinemic (> 520 mlU/l) patients. Since not a single case of macroprolactinemia (recovery <40{\%}) was found in the range of 520-700 mlU/l, only in women with prolactin > 700 mlU/l (N = 254) entered the study. RESULTS: In 59 patients (23{\%}) macroprolactinemia was found. In women, the occurrence of macroprolactinemia increased with advancing age (p <0.05). {"}A priori{"} clinical signs indicating hyperprolactinemia occurred less frequently in patients with macroprolactinemia than in those with true hyperprolactinemia. Pituitary microadenoma was found in 9.8{\%} of macroprolactinemia vs. 31.6{\%} in true hyperprolactinemia (p <0.01); galactorrhea: 4{\%} in macroprolactinemia vs. 19{\%} in true hyperprolactinemia, (p <0.05); infertility: 17{\%} in macroprolactinemia vs. 44{\%} in true hyperprolactinemia (p <0.05). In 8 out of 59 women with macroprolactinemia, true hyperprolactinemia appeared simultaneously (15.3{\%}). Occurrence of polycystic ovaries syndrome was more frequent in the true hyperprolactinemia (12{\%}) that in macroprolactinemia (4.5{\%}). CONCLUSIONS: It has been shown that macroprolactin does not occur in mild hyperprolactinemia. In women, the occurrence of macroprolactinemia increases with age. {"}A priori{"} clinical signs indicating hyperprolactinemia and pituitary abnormality are less frequent in macroprolactinemia than in true hyperprolactinemia. The diagnosis of macroprolactinemia should be used only, when the PRL levels fall to the normal range after precipitation. To avoid diagnostic and therapeutic pitfalls the screening for macroprolactin of all patients with prolactin > 700 mlU/L is recommended.",
author = "Erzs{\'e}bet Toldy and Zolt{\'a}n L{\"o}csei and I. Szabolcs and P{\'a}l Kneffel and M. G{\'o}th and Dominika Sz{\"o}ke and G. Kov{\'a}cs",
year = "2003",
month = "10",
day = "26",
language = "Hungarian",
volume = "144",
pages = "2121--2127",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "43",

}

TY - JOUR

T1 - A macroprolactinaemia és a hyperprolactinaemia differenciáldiagnosztikája.

AU - Toldy, Erzsébet

AU - Löcsei, Zoltán

AU - Szabolcs, I.

AU - Kneffel, Pál

AU - Góth, M.

AU - Szöke, Dominika

AU - Kovács, G.

PY - 2003/10/26

Y1 - 2003/10/26

N2 - INTRODUCTION: Biologically active prolactin and the inactive fraction of macroprolactin can be present in hyperprolactinaemic sera. The reaction of routinely used prolactin assays with macroprolactin is variable. AIMS: The present study was undertaken to analyse the leading clinical signs of hyperprolactinemia in macroprolactinemia and true hyperprolactinemia and to assess the prevalence of macroprolactinemia in hyperprolactinemic females. METHODS: 1571 consecutive female patients were investigated for hyperprolactinemia. Prolactin was measured before and after precipitation of macroprolactin by polyethylene glycol in 285 hyperprolactinemic (> 520 mlU/l) patients. Since not a single case of macroprolactinemia (recovery <40%) was found in the range of 520-700 mlU/l, only in women with prolactin > 700 mlU/l (N = 254) entered the study. RESULTS: In 59 patients (23%) macroprolactinemia was found. In women, the occurrence of macroprolactinemia increased with advancing age (p <0.05). "A priori" clinical signs indicating hyperprolactinemia occurred less frequently in patients with macroprolactinemia than in those with true hyperprolactinemia. Pituitary microadenoma was found in 9.8% of macroprolactinemia vs. 31.6% in true hyperprolactinemia (p <0.01); galactorrhea: 4% in macroprolactinemia vs. 19% in true hyperprolactinemia, (p <0.05); infertility: 17% in macroprolactinemia vs. 44% in true hyperprolactinemia (p <0.05). In 8 out of 59 women with macroprolactinemia, true hyperprolactinemia appeared simultaneously (15.3%). Occurrence of polycystic ovaries syndrome was more frequent in the true hyperprolactinemia (12%) that in macroprolactinemia (4.5%). CONCLUSIONS: It has been shown that macroprolactin does not occur in mild hyperprolactinemia. In women, the occurrence of macroprolactinemia increases with age. "A priori" clinical signs indicating hyperprolactinemia and pituitary abnormality are less frequent in macroprolactinemia than in true hyperprolactinemia. The diagnosis of macroprolactinemia should be used only, when the PRL levels fall to the normal range after precipitation. To avoid diagnostic and therapeutic pitfalls the screening for macroprolactin of all patients with prolactin > 700 mlU/L is recommended.

AB - INTRODUCTION: Biologically active prolactin and the inactive fraction of macroprolactin can be present in hyperprolactinaemic sera. The reaction of routinely used prolactin assays with macroprolactin is variable. AIMS: The present study was undertaken to analyse the leading clinical signs of hyperprolactinemia in macroprolactinemia and true hyperprolactinemia and to assess the prevalence of macroprolactinemia in hyperprolactinemic females. METHODS: 1571 consecutive female patients were investigated for hyperprolactinemia. Prolactin was measured before and after precipitation of macroprolactin by polyethylene glycol in 285 hyperprolactinemic (> 520 mlU/l) patients. Since not a single case of macroprolactinemia (recovery <40%) was found in the range of 520-700 mlU/l, only in women with prolactin > 700 mlU/l (N = 254) entered the study. RESULTS: In 59 patients (23%) macroprolactinemia was found. In women, the occurrence of macroprolactinemia increased with advancing age (p <0.05). "A priori" clinical signs indicating hyperprolactinemia occurred less frequently in patients with macroprolactinemia than in those with true hyperprolactinemia. Pituitary microadenoma was found in 9.8% of macroprolactinemia vs. 31.6% in true hyperprolactinemia (p <0.01); galactorrhea: 4% in macroprolactinemia vs. 19% in true hyperprolactinemia, (p <0.05); infertility: 17% in macroprolactinemia vs. 44% in true hyperprolactinemia (p <0.05). In 8 out of 59 women with macroprolactinemia, true hyperprolactinemia appeared simultaneously (15.3%). Occurrence of polycystic ovaries syndrome was more frequent in the true hyperprolactinemia (12%) that in macroprolactinemia (4.5%). CONCLUSIONS: It has been shown that macroprolactin does not occur in mild hyperprolactinemia. In women, the occurrence of macroprolactinemia increases with age. "A priori" clinical signs indicating hyperprolactinemia and pituitary abnormality are less frequent in macroprolactinemia than in true hyperprolactinemia. The diagnosis of macroprolactinemia should be used only, when the PRL levels fall to the normal range after precipitation. To avoid diagnostic and therapeutic pitfalls the screening for macroprolactin of all patients with prolactin > 700 mlU/L is recommended.

UR - http://www.scopus.com/inward/record.url?scp=17644441638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644441638&partnerID=8YFLogxK

M3 - Article

VL - 144

SP - 2121

EP - 2127

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 43

ER -